RxDoctor Payments Data

Derek Horkey, MD

Glaucoma Specialist · Woodbury, MNNPI 1053759019

Payments from drug & device makers

$6,355in general payments, 2019–2025

Across 65 payments — averaging $97.76 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • NEW World Medical,inc.$5K
  • Glaukos Corporation$924
  • Alcon$722
  • AbbVie$28
  • Sun Pharmaceutical Industries Inc.$25
  • Harrow Eye, LLC$19
  • plus $19 from 1 others

What the payments were for

  • Consulting fees$3255%
  • Speaking & faculty fees$2,50039%
  • Food & beverage$3,53056%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

Too few glaucoma specialist providers in Minnesotato place this figure against a meaningful peer group, so we don't.

Medicare billing

Part B allowed, 2024
$299,000
Medicare patients
613
Services billed
2,196

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
LumiganBimatoprost132$88,477
Latanoprost1,474$36,487
Travoprost118$27,287
RestasisCyclosporine23$27,193
Prednisolone Acetate709$25,257
Brimonidine Tartrate396$25,084
RhopressaNetarsudil Mesylate37$23,271
Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol76$20,194
Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat887$20,043
SimbrinzaBrinzolamide/Brimonidine Tart70$19,537
VyzultaLatanoprostene Bunod24$15,267
Cyclosporine16$12,145
Alphagan PBrimonidine Tartrate30$11,433
Brinzolamide40$10,504
RocklatanNetarsudil Mesylat/Latanoprost16$10,237

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieLumigan, Restasis, Alphagan P, Combigan$28$133,304202 claims
AlconSimbrinza$722$19,53770 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. There are too few glaucoma specialist providers in Minnesotaon file to place this against a meaningful peer group, so we don't.

Other glaucoma specialist in Woodbury

Where these figures come from

Is this you, or does something look wrong? →